Several bioactive compounds have been tested in patients with T2DM for their ability to modulate the NRF2-KEAP1 pathway, thereby inducing key antioxidant enzymes to suppress disease-related inflammation and oxidative stress. The gene discussed is KEAP1; the disease is type 2 diabetes mellitus.